The pharmacological treatment of acquired nystagmus.
We review the latest literature on the neuropharmacological treatments for acquired nystagmus.Nystagmus may have a significant [corrected] impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.
Department of Clinical Neurosciences, Neurology Unit, University of Cambridge, Cambridge, UK.
Arpan R
AR
Mehta
Christopher
C
Kennard
D000588:Amines / Q000627:therapeutic use; D000631:Aminopyridines / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D020417:Nystagmus, Congenital / Q000175:diagnosis / Q000188:drug therapy; D009759:Nystagmus, Pathologic / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D000631:Aminopyridines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D001418:Baclofen; D008559:Memantine